Nanobiotix Appoints New COO to Lead Development of NBTXR3 Therapy for 7 Cancer Types

Nanobiotix Appoints New COO to Lead Development of NBTXR3 Therapy for 7 Cancer Types
Nanobiotix has named senior pharmaceutical executive Alain Dostie its chief operating officer. Dostie will head development of NBTXR3 — a radio-enhancer nanoparticle to treat seven types of cancer including prostate cancer. The company hopes NBTXR3 will win its first European approval in 2017, CEO Laurent Levy said in a news release. “We are thrilled to welcome Alain to the Nanobiotix

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *